## QIBA Ultrasound Shear Wave Speed (SWS)

### **Clinical Applications and Biological Targets Subcommittee Call**

Monday, 17 December 2012; 1 PM CT Call Summary

In attendance RSNA

Claude Cohen-Bacrie, MS (Co-Chair)

Anthony Samir, MD, (Co-Chair)

Michael Andre, PhD

Gilles Guenette, RDMS, RDCS, RVT

Sebastian Mueller, MD

Nicolas Rognin, MSc, PhD

Julie Lisiecki

Laurent Sandrin, PhD

Paul Carson, PhD

Moderator: Mr. Claude Cohen-Bacrie, MS

## Proposed Agenda Clinical Subcommittee, 12/17

- Action points from 11.09.2012 summary
- Debrief of last meeting of QIBA at RSNA (specific discussion on pilot study).
- The literature review (paper to be written)
- Exercise: How to prioritize/organize confounding factors

#### Discussion

- Pragmatic approach suggested when incorporating a review of confounding factors for clinical pilot study protocol
- Suggested categorization and prioritization of confounding factors

# Recap of breakout session for Ultrasound at QIBA Working Meeting, RSNA 2012

- Phantom Study Phase 1 logistics
  - All volunteers to perform given protocol; logistics and procedures
  - o Phantoms are on track to be completed by 12/21 and shipped a few weeks later
  - Initial shipment will be to Dr. Palmeri at Duke University, where inter-phantom variation testing will be performed prior to inter-laboratory testing
  - MRE phantoms will be shipped to Mayo Clinic during the first week of January
    - Larger MRE phantom will not be tested at Duke, but sent directly to Mayo
    - Dr. Andre volunteered to take measurements on the MRE phantom at UCSD, after Mayo
- 2. Pilot study clinical

## Literature Review to include prioritization of confounding factors

- Proposal to identify existing confounding factors and create subgroups in Mendeley
  - o Dr. Palmeri or Ms. Hallam to send Mendeley details to Dr. Sebastian Mueller
- Discussion of how to best utilize the confounding factor list, i.e., for defining acquisition parameters on patients, or assessing the clinical condition of a patient, etc.
  - Determination of where these factors will fit into a protocol document and their impact on measurements will also be necessary
  - Parameters for clinical conditions may introduce a bias in the measurement
- Goal: Defining how indicative liver stiffness is to liver fibrosis using the SWS measurement
- Problem: Side effects of clinical conditions, e.g., inflammation, fatty content of the liver, etc.
  - Selection of patients with a very pronounced confounding factor will be helpful
- Consideration of most significant variables that contribute to differences among systems by the subcommittee
  - o Clinical protocol work could be done by building on the work of the Phantom Subcommittee
- Question as to whether it would be necessary to address the confounding factors, if standardization across machines is possible.

### **Next Steps:**

- 1. Dr. Samir to draft a standardized case report form for group review
- All members to contribute to the list of Dependencies (Confounders), especially to practical recommendations
- **3.** Dr. Nelson to update the group on progress with DICOM when available.
- 4. Dr. Palmeri or Ms. Hallam to send Mendeley details to Dr. Sebastian Mueller for inclusion

### Next QIBA US SWS subcommittee calls (2013):

- January 7 US SWS Technical Committee, 1 pm CT, Monday
- January 14
   Phantom System Testing and Measurement Subcommittee, 1 pm CT, Monday
- January 18 System Dependencies Subcommittee, 11 am CT, Friday
- January 21
   Clinical Applications and Biological Targets Subcommittee, 1 pm CT, Monday

logging on to the WebEx, identification is not possible Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries. QIBA wiki